Milestone Pharmaceuticals Stock (MIST) Down 30% After Announcing Proposed Public Offering.

Milestone Pharmaceuticals (MIST) stock fell 32.03% on Friday after the biopharmaceutical company announced plans for a proposed public offering. The funds raised will be used for clinical development and commercial launch of etripamil, as well as for working capital and general corporate purposes. The offering will include shares of common stock and warrants that holders can exercise for additional shares.

Milestone Pharmaceuticals (MIST) stock experienced a significant drop on Friday, July 2, 2025, following the company's announcement of a proposed public offering. The biopharmaceutical company plans to issue shares of common stock and warrants that holders can exercise for additional shares, aiming to raise funds for clinical development and commercial launch of etripamil, as well as for working capital and general corporate purposes.

The stock fell by 32.03% during pre-market trading, marking a substantial sell-off of over 1.2 million shares compared to the three-month daily average of about 688,000 shares. Traders are uncertain about the specifics of the offering, including the number of shares and warrants, and their respective pricing, which has contributed to the negative market reaction.

Milestone Pharmaceuticals has not yet finalized the details of the public offering, but the funds raised will be used to support the company's ongoing clinical development and commercial launch of etripamil, a nasal spray intended to treat paroxysmal supraventricular tachycardia (PSVT). The offering is expected to close around July 14, 2025, subject to customary closing conditions.

Analysts' consensus rating for Milestone Pharmaceuticals remains Moderate Buy, with an average price target of $5, representing a potential 96.31% upside for the shares. Despite the recent stock movement, the company maintains a healthy current ratio of 4.67 and operates with moderate debt, indicating a solid financial foundation.

Milestone Pharmaceuticals recently submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for etripamil, which is currently under review. The FDA has set a target action date of December 13, 2025, for Milestone's CARDAMYST nasal spray, an investigational therapy for PSVT. The company has also extended its $75 million royalty purchase agreement with RTW Investments, LP, until December 31, 2025, to support the commercial launch of CARDAMYST following expected FDA approval.

References:

[1] https://www.tipranks.com/news/why-is-milestone-pharmaceuticals-stock-mist-down-30-today
[2] https://uk.investing.com/news/company-news/milestone-pharmaceuticals-prices-525-million-public-offering-93CH-4166033
[3] https://investors.milestonepharma.com/news-releases/news-release-details/milestone-pharmaceuticals-announces-fda-acceptance-companys